Poster 292

Precision Cut Cancer Tissue Slices derived from cancer patients as a tool for the investigation of immune-modulatory compounds

Kristina Bernoth, Mirja Piller, Moiken Petersen, Olivia Timm, Jana Krüger, Hartmut Juhl, Kerstin A. David and Nicole Grabinski

especially in respect of protein expression changes and cytokine release.

Methods


Procedure. Informed consent was obtained from all patients.

into 500 µm slices using a Krumdieck[™] tissue slicer (TSE Systems).

analysis of T-cells.

were run on the Peggy Sue instrument.

condition were pooled and analyzed.



cultures using the validated ten-plex proinflammatory panel from MSD. Shown is the mean value with standard deviation of cytokines in pg/ml compared to the untreated control.

umor ontent [%]	Infiltration of CD3-positive cells					
	Tumor region					
	HPF1	HPF2	HPF3	HPF4	HPF5	Average
30	165	183	98	208	252	186
25	143	127	232	272	243	203
40	64	110	156	241	76	129




Figure 5: Simple Western Size analysis of untreated and Nivolumab treated tissue slices. PCCTS were treated with 20 µg/ml Nivolumab for 18 h. Protein expression of precision cut cancer tissue slices was analyzed using anti-PD-1 (A), anti-PD-L1 (B), anti-pAKT (C) and anti-pS6RP (D) antibodies. Shown is both, the lane view and electropherogram view of software generated peak fit.

Cytokine release upon Nivolumab treatment




Figure 6: Cytokine secretion of untreated and Nivolumab treated PCCTS from one NSCLC patient (V1197). PCCTS were treated with 20 µg/ml Nivolumab for 18 hours. Cytokine secretion was analyzed in supernatants of tissue slices using the validated ten-plex proinflammatory panel from MSD. Shown is the mean value with standard deviation of cytokines in pg/ml compared to the untreated control.

Conclusion and Summary

- IFN- γ , IL-2, and TNF- α were detectable.



OKT3 treatment induced cytokine secretion into the supernatant. Especially high levels of

• Nivolumab treatment induced secretion of IFN-y and IL-2.

• Upon treatment with Nivolumab, expression of pAKT and pS6RP was decreased.

• The model of PCCTS is suitable for pre-clinical evaluation of immunomodulatory compounds.